Stockscreener 앱 받기
4.41
13.22%
0.515
전일 마감가:
$3.895
열려 있는:
$3.96
하루 거래량:
31,768
Relative Volume:
1.39
시가총액:
$678.64M
수익:
$117.10K
순이익/손실:
$-161.61M
주가수익비율:
-1.833
EPS:
-2.4059
순현금흐름:
-
1주 성능:
+15.45%
1개월 성능:
+32.03%
6개월 성능:
+108.02%
1년 성능:
+59.21%
1일 변동 폭
$3.96
$4.41
1주일 범위
$3.59
$4.41
52주 변동 폭
$1.79
$5.45
Opthea Limited Adr Stock (OPT) Company Profile
OPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OPT
Opthea Limited Adr
|
4.41 | 678.64M | 117.10K | -161.61M | 0 | -2.4059 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Opthea Limited Adr Stock (OPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-08 | 개시 | H.C. Wainwright | Buy |
| 2022-04-26 | 개시 | SVB Leerink | Outperform |
| 2020-11-17 | 개시 | Citigroup | Buy |
| 2020-11-11 | 개시 | Oppenheimer | Outperform |
| 2020-11-11 | 개시 | SVB Leerink | Outperform |
| 2020-11-11 | 개시 | Truist | Buy |
모두보기
Opthea Limited Adr 주식(OPT)의 최신 뉴스
Jane Street Group LLC Invests $114,000 in Opthea Limited (NASDAQ:OPT) - Defense World
Opthea’s Innovative Approach to AMD Treatment with Sozinibercept - TipRanks
Opthea to Host Investor Days in New York and Australia - The Manila Times
OPTOpthea Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
EX-99.1 - SEC.gov
Opthea to Present Phase 3 Trial Update at J.P. Morgan Healthcare Conference - TipRanks
Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Opthea to Present Phase 3 AMD Trial Data at JP Morgan Healthcare Conference - StockTitan
Opthea's Wet AMD Program to be Featured at FLORetina 2024 - The Manila Times
Opthea’s Wet AMD Program to be Featured at FLORetina 2024 - Yahoo Finance
Opthea Highlights Innovative Wet AMD Therapy - TipRanks
Opthea to Participate in Citi 2024 Global Healthcare Conference - Yahoo Finance
Opthea Limited to Engage Investors at Healthcare Conference - TipRanks
Opthea CEO to Present at Citi Healthcare Conference, Spotlights Eye Disease Treatment - StockTitan
Opthea Limited Targets AMD Market with Sozinibercept - TipRanks
Opthea Appoints Kathy Connell to Board of Directors - The Manila Times
Opthea Appoints Kathy Connell to Board of Directors - GlobeNewswire Inc.
Opthea : Chairman’s Address to the 2024 Annual General Meeting Form 6 K - Marketscreener.com
Opthea Limited Announces Board Changes - Marketscreener.com
Opthea's Sozinibercept Shows Superior Results in Phase 2b Eye Disease Trial - StockTitan
Opthea's Wet AMD Program Featured at Ophthalmology Events - The Manila Times
Opthea (NASDAQ:OPT) Shares Up 1.7% – What’s Next? - Defense World
Opthea to Participate in November Investor Conferences - The Manila Times
Opthea : UPDATE Opthea to Participate in November Investor Conferences Form 6 K - Marketscreener.com
Opthea Limited Strengthens Leadership and Advances AMD Treatment - TipRanks
FY2025 EPS Estimates for Opthea Lifted by Leerink Partnrs - Defense World
Is Opthea Limited (OPT) the Penny Stock with the Biggest Upside Potential According to Analysts? - Insider Monkey
Opthea Files Notice of Annual General Meeting - The Manila Times
Opthea Ltd stock soars to 52-week high, touches $4.95 - Investing.com India
Opthea Ltd stock soars to 52-week high, touches $4.95 By Investing.com - Investing.com South Africa
Opthea Wet AMD Program to be Presented at Innovate Retina - The Manila Times
Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025 - The Manila Times
Opthea Limited Announces Chief Financial Officer Changes - Marketscreener.com
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024 - The Manila Times
Opthea Advances Retinal Disease Treatments - TipRanks
Opthea Advances nAMD Treatment with Sozinibercept - TipRanks
Opthea Joins the S&P/ASX 300 Index - StockTitan
Opthea Limited (NASDAQ:OPT) Shares Sold by Victory Capital Management Inc. - Defense World
Opthea Advances Toward Sozinibercept Commercialization - TipRanks
Opthea’s Sozinibercept Eyes Breakthrough in AMD Therapy - TipRanks
FY2025 EPS Estimates for Opthea Limited Boosted by HC Wainwright (NASDAQ:OPT) - Defense World
Research Analysts Set Expectations for Opthea Limited’s FY2029 Earnings (NASDAQ:OPT) - Defense World
Opthea Prepares for Phase 3 Results with Leadership Revamp - TipRanks
Opthea (NASDAQ:OPT) Given New $12.00 Price Target at HC Wainwright - Defense World
Opthea Limited Showcases Innovations at Investor Conferences - TipRanks
Opthea Limited: Revenues Up, Losses Widen - TipRanks
Opthea Reports Full-Year Financial Results and Business Updates - Morningstar
Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024 - Morningstar
Opthea Limited Showcases at Ophthalmology Event - TipRanks
'Blockbuster opportunity': This speculative ASX stock could rise 70% - The Motley Fool Australia
Opthea forms global medical advisory board for retinal diseases - Investing.com India
Opthea Limited Adr (OPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):